{"product_id":"adxn-vrio-analysis","title":"Addex Therapeutics Ltd (ADXN): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to Addex Therapeutics Ltd (ADXN)'s sustained success! This VRIO analysis distills the company's competitive foundation down to its essence, revealing precisely how its resources measure up on the critical axes of Value, Rarity, Inimitability, and Organization, leading to the stark conclusion: \u0026amp;O4\u0026amp;. Scroll down now to grasp the full strategic implications of this assessment and see what truly drives Addex Therapeutics Ltd (ADXN)'s market position.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAddex Therapeutics Ltd (ADXN) - VRIO Analysis: 1. Allosteric Modulator Platform Technology\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the core engine of Addex Therapeutics Ltd, the Allosteric Modulator Platform. This isn't just another drug discovery tool; it’s their specialized way of designing small molecules that fine-tune receptors, aiming for better precision than standard drugs. The real test of this platform is whether it translates into clinical wins and financial stability, which, honestly, is always the tightrope walk in biotech.\u003c\/p\u003e\n\n\u003ch\u003eValue Assessment\u003c\/h\u003e\n\u003cp\u003eThe platform’s value lies in its ability to create novel, potentially more precise small molecule drugs for tough neurological issues. We see this value validated by the pipeline activity. For instance, the GABAB PAM drug candidate for chronic cough showed robust anti-tussive activity in disease models during H1 2025. Also, the partnership with Indivior, where their GABAB PAM candidate for substance use disorders completed IND-enabling studies in H1 2025, is a huge external validation of the platform’s capability. If those programs hit milestones, Addex is eligible for up to USD 330 million plus royalties.\u003c\/p\u003e\n\n\u003ch\u003eRarity and Imitability\u003c\/h\u003e\n\u003cp\u003eSpecialized expertise in allosteric modulation is definitely not common, giving Addex a high bar for Rarity. It’s not just about having the idea; it’s about the deep, proprietary scientific knowledge and the specific screening\/design capabilities needed to execute it. This makes it difficult to imitate. Think of it like a master chef’s secret sauce - you can buy the ingredients, but replicating the technique takes years of specialized practice. The fact that a major player like Perceptive Advisors invested $63 million to spin out preclinical assets into Neurosterix, while keeping a 20% stake, speaks volumes about the perceived rarity and value of the underlying technology.\u003c\/p\u003e\n\n\u003ch\u003eOrganization for Exploitation\u003c\/h\u003e\n\u003cp\u003eOrganization is where things get tricky for Addex right now. On one hand, the pipeline progress - advancing the cough candidate, regaining rights to the Phase 2 mGlu2 PAM asset (ADX71149), and securing the Sinntaxis option for mGlu5 NAM in brain injury - shows they can effectively apply the platform to generate assets. But, the financial reality is stark. The cash position at the end of H1 2025 was only CHF 2.3 million. That tight liquidity limits their ability to fully exploit the platform without external funding or major milestones hitting. It’s a moderate organization score because the science is moving, but the balance sheet is restricting full operational scale.\u003c\/p\u003e\n\n\u003ch\u003eCompetitive Advantage Summary\u003c\/h\u003e\n\u003cp\u003eThe platform currently holds a \u003cstrong\u003eTemporary Competitive Advantage\u003c\/strong\u003e. The technology itself is rare and hard to copy, but a sustained advantage in this sector hinges on clinical success and, critically for Addex, securing adequate funding. The platform’s value is proven by the quality of the assets it has generated, but until a drug candidate moves successfully through late-stage trials or a major financing event occurs, the advantage remains conditional. The basic and diluted loss per share for H1 2025 was CHF 0.03, showing the burn rate is still a factor.\u003c\/p\u003e\n\n\u003cp\u003eHere is a quick mapping of the VRIO dimensions against the platform’s current state:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eKey Supporting Data (2025 Fiscal Year)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue (V)\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eRobust preclinical data for GABAB PAM (cough); Partnered asset (Indivior) through IND-enabling studies.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity (R)\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eSpecialized allosteric modulator expertise; Validation via $63 million Neurosterix spin-out funding.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability (I)\u003c\/td\u003e\n\u003ctd\u003eDifficult\u003c\/td\u003e\n\u003ctd\u003eRequires deep, proprietary scientific knowledge and screening capabilities.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (O)\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003ePipeline advancing, but cash at H1 2025 was only CHF 2.3 million, constraining full exploitation.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eAdvantage contingent on clinical trial success and resolving cash runway constraints.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is the inherent binary risk of clinical development; one failed Phase 2 trial can wipe out the perceived value of the platform overnight. Still, the platform is the source of all potential upside here. You need to watch the next data readout for the chronic cough program closely.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePlatform validated by 20% Neurosterix equity stake.\u003c\/li\u003e\n\u003cli\u003ePotential milestone payments up to USD 330 million from Indivior.\u003c\/li\u003e\n\u003cli\u003eCash position of CHF 2.3 million as of June 30, 2025.\u003c\/li\u003e\n\u003cli\u003eRegained rights to Phase 2 asset ADX71149.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAddex Therapeutics Ltd (ADXN) - VRIO Analysis: 2. GABAB PAM Program (Chronic Cough Indication)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Targets a large, under-served market with a candidate showing robust anti-tussive activity in preclinical models. The indication represents a solid commercial opportunity due to significant unmet medical need.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; other companies target cough, but a validated GABAB PAM approach here is less common. Activating GABAB receptors has been clinically validated with baclofen, but the PAM approach is novel for this indication.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; the specific compound and preclinical data package are unique to Addex. IND-enabling studies are ready to start, pending financing.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; in-house development suggests strong internal focus and control over this lead asset. The company has selected a drug candidate to advance its independent GABAB PAM program for chronic cough. However, the company's cash position at the end of 2024 was CHF 3.3 million, and CHF 2.3 million at the end of H1 2025, indicating a need for external financing to advance unpartnered programs into the clinic.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; success in Phase 1\/2 trials will be the true test of its market advantage. The GABAB PAM candidate is planned to start IND enabling studies in 2025, subject to funding.\u003c\/p\u003e\n\u003cp\u003eThe preclinical profile of the GABAB PAM candidate demonstrates potential for a best-in-class treatment compared to the off-label standard of care, baclofen.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAttribute\u003c\/th\u003e\n\u003cth\u003eAddex GABAB PAM Candidate (Preclinical)\u003c\/th\u003e\n\u003cth\u003eReference Drug: Baclofen (GABAB Agonist)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMechanism\u003c\/td\u003e\n\u003ctd\u003ePositive Allosteric Modulator (PAM)\u003c\/td\u003e\n\u003ctd\u003eOrthosteric Agonist\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEfficacy (Citric Acid Model)\u003c\/td\u003e\n\u003ctd\u003eSignificantly and dose-dependently reduced cough frequency; Minimal efficacious dose 1 mg\/kg\u003c\/td\u003e\n\u003ctd\u003eExhibits antitussive properties\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTolerability\/Safety Margin\u003c\/td\u003e\n\u003ctd\u003eWider safety margin; better tolerability than baclofen\u003c\/td\u003e\n\u003ctd\u003eLimited use due to serious side effects and central nervous system side effects (e.g., sedation)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTolerance\/Efficacy Loss\u003c\/td\u003e\n\u003ctd\u003eShowed no signs of tolerance after sub-chronic treatment\u003c\/td\u003e\n\u003ctd\u003eGradual loss of efficacy during chronic treatment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHalf-life\u003c\/td\u003e\n\u003ctd\u003eImplied improvement for once-daily potential\u003c\/td\u003e\n\u003ctd\u003eShort half-life\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe robust anti-tussive activity observed in preclinical models is quantified by specific efficacy metrics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSignificantly and dose-dependently reduced citric acid-induced cough frequency in guinea pig models.\u003c\/li\u003e\n\u003cli\u003eThe minimal efficacious dose (MED) was established at 1 mg\/kg in guinea pig models.\u003c\/li\u003e\n\u003cli\u003eIncreased cough latency in models of chronic cough.\u003c\/li\u003e\n\u003cli\u003eDemonstrated no signs of tolerance following sub-chronic treatment.\u003c\/li\u003e\n\u003cli\u003eAntitussive efficacy appeared superior to nalbuphine, baclofen, codeine, or a P2X3 inhibitor in the same model.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eContinuing R\u0026amp;D expenses for the GABAB PAM program were CHF 0.9 million in 2024.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAddex Therapeutics Ltd (ADXN) - VRIO Analysis: 3. Dipraglurant (mGlu5 NAM) Repositioning\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Repurposing a Phase 2 asset into the high-need area of brain injury recovery (post-stroke\/TBI) offers a faster path to potential value. Preclinical data in stroke animal models demonstrated that dipraglurant significantly restored functional control after just \u003cstrong\u003ethree days\u003c\/strong\u003e of once-daily treatment. There are currently no approved drugs that promote functional recovery post-stroke.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; having a Phase 2 asset ready for a new indication is a rare find for a company with a Market Cap of \u003cstrong\u003eCHF10.84M\u003c\/strong\u003e (as of Q1 2025 context).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; the clinical data and material exist, but the specific repositioning strategy is theirs. Phase 1 PET study data showed \u003cstrong\u003e27 percent\u003c\/strong\u003e mGlu5 receptor occupancy after a \u003cstrong\u003e100 mg\u003c\/strong\u003e dose of dipraglurant.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the Sinntaxis agreement shows they are organized to explore this new indication actively. The agreement entails an \u003cstrong\u003eundisclosed option fee\u003c\/strong\u003e to Sinntaxis for exclusive IP access. The company's cash position at the end of Q1 2025 was \u003cstrong\u003eCHF 2.8 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the advantage hinges on quickly generating positive human data in the new indication. A Phase 2a study is planned, subject to funding.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\/Status\u003c\/th\u003e\n\u003cth\u003eReference Period\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsset Status\u003c\/td\u003e\n\u003ctd\u003ePhase 2 mGlu5 NAM\u003c\/td\u003e\n\u003ctd\u003eRepositioning for Brain Injury Recovery\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreclinical Efficacy (Stroke Model)\u003c\/td\u003e\n\u003ctd\u003eRestored functional control after \u003cstrong\u003ethree days\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eOnce-daily treatment in animal models\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSinntaxis Agreement Fee\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eUndisclosed\u003c\/strong\u003e option fee\u003c\/td\u003e\n\u003ctd\u003eOption agreement for exclusive IP license\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position (Latest Reported)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eCHF 2.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEnd of H1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss from Continuing Operations\u003c\/td\u003e\n\u003ctd\u003eIncreased by \u003cstrong\u003eCHF 2.4 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e2024 vs 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 1 Receptor Occupancy (100 mg dose)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e27 percent\u003c\/strong\u003e occupancy\u003c\/td\u003e\n\u003ctd\u003eHealthy Volunteers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe company's General \u0026amp; Administrative (G\u0026amp;A) expenses for the full year 2024 were \u003cstrong\u003eCHF 2.3 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePlanned next step: Commence Phase 2a study, subject to \u003cstrong\u003efunding\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e2024 Diluted Net Gain Per Share: \u003cstrong\u003eCHF 0.04\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Sinntaxis collaboration involves Sinntaxis executing a research plan to complete \u003cstrong\u003epreclinical evaluation\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAddex Therapeutics Ltd (ADXN) - VRIO Analysis: 4. Regained Phase 2 mGlu2 PAM Asset (ADX71149)\n\u003c\/h2\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eThe asset, ADX71149, has completed three Phase 2 studies in schizophrenia, anxious depression, and epilepsy. The original partnership with Janssen provided eligibility for up to €109 million in success-based development and regulatory milestones for schizophrenia and anxious depression indications. Additionally, Addex is eligible for low double-digit royalties on net sales.\u003c\/p\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eRegaining control of a Phase 2 asset from a major pharma partner is unusual and valuable.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eCompetitors cannot easily acquire this specific asset with existing clinical data.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eManagement successfully executed the strategy to bring this asset back in-house in April 2025.\u003c\/p\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eThis is a tangible, non-replicable asset that was previously out-licensed.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eData Point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMaximum Potential Milestones (Original Agreement)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€109 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalty Structure\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eLow double-digit royalties\u003c\/strong\u003e on net sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2 Studies Completed Under Partnership\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eThree\u003c\/strong\u003e (Schizophrenia, Anxious Depression, Epilepsy)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Upfront Fee (2005 Agreement)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Research Funding Period\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2 years\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents (H1 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eCHF 2.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cul\u003e\n\u003cli\u003eThe asset was developed under a research collaboration and license agreement first entered into in 2005.\u003c\/li\u003e\n\u003cli\u003eThe epilepsy Phase 2 study failed to achieve statistical significance for the primary endpoint.\u003c\/li\u003e\n\u003cli\u003eThe partnership with Janssen was terminated for the epilepsy indication in July 2024.\u003c\/li\u003e\n\u003cli\u003eRights to ADX71149 were formally regained by Addex in April 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAddex Therapeutics Ltd (ADXN) - VRIO Analysis: 5. Partnership with Indivior (SUD Program Validation)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e External validation of the GABAB PAM approach by a partner who advanced the candidate through IND-enabling studies, reducing Addex's near-term development cost risk. The initial agreement included an upfront payment of \u003cstrong\u003e$5 million\u003c\/strong\u003e and \u003cstrong\u003e$4 million\u003c\/strong\u003e in committed research funding over two years, with potential milestones up to \u003cstrong\u003e$330 million\u003c\/strong\u003e plus tiered royalties up to \u003cstrong\u003edouble-digit\u003c\/strong\u003e percentages. The program also received a \u003cstrong\u003e$5.3 million\u003c\/strong\u003e grant from the National Institute on Drug Abuse (NIDA). Subsequent extensions provided additional funding, such as \u003cstrong\u003eUSD 1 million\u003c\/strong\u003e in December 2022 and \u003cstrong\u003eSFr2.7m ($3m)\u003c\/strong\u003e in a later extension. The successful completion of IND-enabling studies by Indivior in May 2025 marks a significant de-risking event.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; pharma collaborations are common, but the specific validation milestone of a partner advancing a candidate through IND-enabling studies is program-specific.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; the existing agreement, including the specific terms and the progress made (e.g., selection of clinical candidates in August 2024), cannot be copied by competitors.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the partnership structure effectively shares risk and validates the science, evidenced by the structured financial contributions and milestone framework.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the advantage lasts as long as the partnership remains active and productive, with Indivior undertaking all future development of their selected compound.\u003c\/p\u003e\n\u003cp\u003eThe financial structure of the collaboration is summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Component\u003c\/td\u003e\n\u003ctd\u003eAmount\/Term\u003c\/td\u003e\n\u003ctd\u003eReference\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Payment (Initial)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommitted Research Funding (Initial)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$4 million\u003c\/strong\u003e over two years\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential Milestone Payments\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$330 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003eTiered up to \u003cstrong\u003edouble-digit\u003c\/strong\u003e percentages\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIDA Grant Awarded\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExtension Funding (Dec 2022)\u003c\/td\u003e\n\u003ctd\u003eAdditional \u003cstrong\u003eUSD 1 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExtension Funding (Later)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSFr2.7m ($3m)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eKey aspects of the partnership's progression include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe agreement commenced in January 2018.\u003c\/li\u003e\n\u003cli\u003eIndivior selected a compound for future development in substance use disorder in August 2024.\u003c\/li\u003e\n\u003cli\u003eThe selected compound successfully advanced through IND enabling studies as of May 2025.\u003c\/li\u003e\n\u003cli\u003eAddex retained the right to select compounds for its own independent GABAB PAM program, including for chronic cough.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAddex Therapeutics Ltd (ADXN) - VRIO Analysis: 6. Option Agreement with Sinntaxis (IP Access)\n\u003c\/h2\u003e\n\u003cp\u003eThe Option Agreement with Sinntaxis AB, announced on \u003cstrong\u003eApril 30, 2025\u003c\/strong\u003e, secures access to intellectual property for repositioning the \u003cstrong\u003edipraglurant\u003c\/strong\u003e asset (mGlu5 NAM) in brain injury recovery.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Component\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eSupporting Data\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eProvides access to additional intellectual property for the mGlu5 NAM in brain injury recovery, broadening the scope of the repositioning effort.\u003c\/td\u003e\n\u003ctd\u003eThe agreement centers on \u003cstrong\u003edipraglurant\u003c\/strong\u003e for brain injury recovery, building on data published in \u003cem\u003eBrain\u003c\/em\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eLow; option agreements are standard deal structures in the industry.\u003c\/td\u003e\n\u003ctd\u003eThe agreement involves an \u003cstrong\u003eundisclosed option fee\u003c\/strong\u003e paid by Addex.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability\u003c\/td\u003e\n\u003ctd\u003eLow; the specific IP and terms are unique to this agreement.\u003c\/td\u003e\n\u003ctd\u003eThe collaboration includes Sinntaxis executing a research plan to complete preclinical evaluation.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eModerate; it shows a proactive approach to maximizing the dipraglurant asset's potential.\u003c\/td\u003e\n\u003ctd\u003eAddex reported a cash position of \u003cstrong\u003eCHF 2.8 million\u003c\/strong\u003e at the end of Q1 2025, following the agreement announcement.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eNone; this is a standard business development tool, not a source of sustained advantage.\u003c\/td\u003e\n\u003ctd\u003eThe agreement is a strategic collaboration to advance a key clinical asset.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe terms mandate Addex to pay Sinntaxis an \u003cstrong\u003eundisclosed option fee\u003c\/strong\u003e for the exclusive license.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe collaboration involves Sinntaxis completing the preclinical validation of \u003cstrong\u003edipraglurant\u003c\/strong\u003e in models of brain injury recovery.\u003c\/li\u003e\n\u003cli\u003eThe agreement was executed as an option- and collaboration agreement.\u003c\/li\u003e\n\u003cli\u003eThe objective is to treat functional recovery in patients with stroke or traumatic brain injury.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAddex Therapeutics Ltd (ADXN) - VRIO Analysis: 7. Equity Stake in Neurosterix LLC\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides exposure to an emerging preclinical portfolio (like M4 PAM for schizophrenia) without bearing the full R\u0026amp;D cost, offering potential financial upside. The transaction included an immediate cash component of \u003cstrong\u003eCHF 5.0 million\u003c\/strong\u003e and a \u003cstrong\u003e20%\u003c\/strong\u003e equity interest in Neurosterix LLC.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; strategic equity investments in spin-offs or related entities are not unheard of but offer unique upside through the \u003cstrong\u003e20%\u003c\/strong\u003e stake in a separately capitalized entity, which raised \u003cstrong\u003eUSD 65 million\u003c\/strong\u003e in Series A funding.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; the specific equity stake and relationship are proprietary, established via the sale of the drug discovery platform and preclinical portfolio on April 2, 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate; it diversifies risk exposure away from 100% internal focus. The structure resulted in a reported share of net loss from the Neurosterix Group of \u003cstrong\u003eCHF 0.9 million\u003c\/strong\u003e for the three months ended March 31, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the value is tied to Neurosterix's future success and the liquidity of that stake, which was valued at \u003cstrong\u003eCHF 9.4 million\u003c\/strong\u003e as of September 30, 2024.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEquity Stake Percentage\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e20%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eApril 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Received (Neurosterix Transaction)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eCHF 5.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eApril 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeurosterix Series A Funding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUSD 65 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEquity Stake Valuation\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eCHF 9.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShare of Net Loss from Neurosterix Group\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eCHF 0.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ1 2025 (three months ended March 31, 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eThe preclinical portfolio within Neurosterix includes M4 PAM for schizophrenia, mGlu7 NAM for mood disorders, and mGlu2 NAM for mild neurocognitive disorders.\u003c\/li\u003e\n\u003cli\u003eThe total proceeds from the Neurosterix Transaction, as of Q3 2024, comprised the \u003cstrong\u003eCHF 5.0 million\u003c\/strong\u003e cash and the \u003cstrong\u003e20%\u003c\/strong\u003e equity stake valued at \u003cstrong\u003eCHF 9.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe \u003cstrong\u003eCHF 5.0 million\u003c\/strong\u003e cash proceeds partially offset cash used in operating activities, contributing to a cash balance increase to \u003cstrong\u003eCHF 2.8 million\u003c\/strong\u003e at March 31, 2025, from \u003cstrong\u003eCHF 1.6 million\u003c\/strong\u003e at March 31, 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAddex Therapeutics Ltd (ADXN) - VRIO Analysis: 8. Clinical and Translational Science Team\n\u003c\/h2\u003e\n\u003cp\u003eThe analysis below reflects the capabilities of the Clinical and Translational Science Team at Addex Therapeutics Ltd.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThe expertise supports the advancement of multiple distinct small molecule programs through preclinical stages and management of Phase 2 assets. This includes GABAB, mGlu2, and mGlu5 programs. The team's work resulted in the GABAB PAM chronic cough candidate demonstrating robust anti-tussive activity in multiple preclinical models. Furthermore, the team managed the repositioning of the mGlu5 NAM asset, dipraglurant, into brain injury recovery.\u003c\/p\u003e\n\u003cp\u003ePipeline Progression Milestones:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGABAB PAM Substance Use Disorder program advanced successfully through IND enabling studies with partner Indivior.\u003c\/li\u003e\n\u003cli\u003eRights to the Phase 2 mGlu2 PAM asset, ADX71149, were regained by Addex.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinancial context related to R\u0026amp;D execution:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2023 Amount (CHF)\u003c\/th\u003e\n\u003cth\u003e2024 Amount (CHF)\u003c\/th\u003e\n\u003cth\u003eQ1 2024 vs Q1 2025 Change (CHF)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses (Continuing Operations)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecrease of \u003cstrong\u003e0.1 million\u003c\/strong\u003e (Q1 2024 to Q1 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eDeep, focused CNS translational science talent in allosteric modulation is scarce. The team's experience spans multiple receptor types (GABAB, mGlu2, mGlu5). The average tenure of the management team is noted at \u003cstrong\u003e8.7 years\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eDifficult due to the specialized scientific talent required and the lean organizational structure, evidenced by R\u0026amp;D expenses decreasing from \u003cstrong\u003eCHF 1.2 million\u003c\/strong\u003e in FY 2023 to \u003cstrong\u003eCHF 0.8 million\u003c\/strong\u003e in FY 2024. The team structure relies on internal resources complemented by consultants and service providers.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eHigh; the team is demonstrably capable of managing diverse, complex programs simultaneously, as shown by the portfolio status.\u003c\/p\u003e\n\u003cp\u003eCurrent Pipeline Assets Under Team Oversight\/Management:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGABAB PAM for Chronic Cough (Independent development).\u003c\/li\u003e\n\u003cli\u003eDipraglurant (mGlu5 NAM) for Post-Stroke \/ TBI Recovery.\u003c\/li\u003e\n\u003cli\u003eADX71149 (mGlu2 PAM) (Rights regained).\u003c\/li\u003e\n\u003cli\u003eM4 PAM for Schizophrenia (via \u003cstrong\u003e20%\u003c\/strong\u003e equity interest in Neurosterix).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained; human capital and institutional knowledge in the niche area of allosteric modulation are hard to replicate quickly. The company maintained a cash position of \u003cstrong\u003eCHF 2.8 million\u003c\/strong\u003e as of Q1 2025.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAddex Therapeutics Ltd (ADXN) - VRIO Analysis: 9. Cash Position and Financial Runway (as of H1 2025)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The \u003cstrong\u003eCHF 2.3 million\u003c\/strong\u003e cash position at the end of H1 2025 provides a runway to fund operations, though it is tight, necessitating immediate financing action.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; a low cash balance is common for clinical-stage biotechs burning cash.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; this is a financial metric, not a capability, and it is a constraint.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate; management is organized to stretch this limited capital, but it requires constant vigilance.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e None; in fact, it represents a significant near-term risk that requires immediate action, like securing new funding. Finance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\u003cp\u003eThe financial context surrounding the H1 2025 cash position is detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount (CHF)\u003c\/th\u003e\n\u003cth\u003ePeriod End Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJune 30, 2025 (H1 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e3.8 million\u003c\/td\u003e\n\u003ctd\u003eJune 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e2.8 million\u003c\/td\u003e\n\u003ctd\u003eMarch 31, 2025 (Q1 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBasic and Diluted Loss Per Share\u003c\/td\u003e\n\u003ctd\u003e0.03 per share\u003c\/td\u003e\n\u003ctd\u003eSix months ended June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBasic and Diluted Profit Per Share\u003c\/td\u003e\n\u003ctd\u003e0.10 per share\u003c\/td\u003e\n\u003ctd\u003eSix months ended June 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eKey financial observations related to liquidity and operational burn include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash and cash equivalents decreased by \u003cstrong\u003eCHF 1.5 million\u003c\/strong\u003e between June 30, 2025, and June 30, 2024, primarily due to operating activities.\u003c\/li\u003e\n\u003cli\u003eThe Q1 2025 cash balance of \u003cstrong\u003eCHF 2.8 million\u003c\/strong\u003e was projected to ensure operations through mid-2026 based on earlier reporting.\u003c\/li\u003e\n\u003cli\u003eThe company reported a net loss of \u003cstrong\u003eCHF 1.47 million\u003c\/strong\u003e for Q1 2025.\u003c\/li\u003e\n\u003cli\u003eOperating loss for Q1 2025 was \u003cstrong\u003eCHF 606,262\u003c\/strong\u003e, with no revenue from contracts with customers during that quarter.\u003c\/li\u003e\n\u003cli\u003eTotal assets decreased from \u003cstrong\u003eCHF 10.68 million\u003c\/strong\u003e at the end of 2024 to \u003cstrong\u003eCHF 9.48 million\u003c\/strong\u003e by March 2025.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516103319701,"sku":"adxn-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/adxn-vrio-analysis.png?v=1740141769","url":"https:\/\/dcf-model.com\/fr\/products\/adxn-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}